This is a record fundraising for an unlisted French biotech.
ImCheck Therapeutics, a company specializing in the fight against cancer and immunology, has just completed a funding round of 96 million euros.
The operation was co-led by the German fund Earlybird and the French Andera Partners, alongside historical investors, including Kurma Partners, Eurazeo, Pfizer Ventures and Bpifrance.
This funding should allow ImCheck to continue the clinical trials of its first drug candidate in immuno-oncology (phase II) and to start those of its other molecules, in immuno-oncology, but also in autoimmune and infectious diseases.
The company, created in 2015 in Marseille, also plans to expand its teams in Europe and the United States, where it will launch its trials.
"
It took us a year, in a tense market, to carry out this fundraising which will allow us to take a new step”,
declares Pierre d’Epenoux, president…
This article is for subscribers only.
You have 60% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/UFLZRSS3JBJLBP66RM6Q4AKJ4M.jpg)
